

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Edmund J. Wood, the Chapter 7 Bankruptcy Trustee for Kaleidos Pharma, Inc.	04/03/2007
RECEIVING PARTY DATA	
Name:	Applied Protein Sciences, LLC
Street Address:	650 Castro Street
Internal Address:	Suite 120-333
City:	Mountain View
State/Country:	CALIFORNIA
Postal Code:	94041
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	10050190
CORRESPONDENCE DATA	
Fax Number:	(650)969-8203
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	(650) 969-8300
Email:	htran@imsciences.com
Correspondent Name:	Hannah Tran
Address Line 1:	650 Castro Street
Address Line 2:	Suite 220
Address Line 4:	Mountain View, CALIFORNIA 94041
NAME OF SUBMITTER:	Hannah Tran

OP \$40.00 10050190

Total Attachments: 6
 source=Assignment_AppliedProtein#page1.tif
 source=Assignment_AppliedProtein#page2.tif
 source=Assignment_AppliedProtein#page3.tif
 source=Assignment_AppliedProtein#page4.tif

PATENT

500257062

REEL: 019149 FRAME: 0448

source=Assignment_AppliedProtein#page5.tif
source=Assignment_AppliedProtein#page6.tif

ASSIGNMENT OF PATENT RIGHTS

For good and valuable consideration, the receipt of which is hereby acknowledged, **Edmund J. Wood**, the Chapter 7 Bankruptcy Trustee for **Kaleidos Pharma, Inc.** (formerly known as **Stem Cell Pharmaceuticals, Inc.**), having offices at 303 N 67th Street, Seattle, WA 98103 ("**Assignor**"), does hereby sell, assign, transfer, and convey unto **Applied Protein Sciences, LLC**, a California limited liability company, with an office at 650 Castro Street, Suite 120-333, Mountain View, CA 94041 ("**Assignee**"), or its designees all right, title, and interest that exist today and may exist in the future in and to all of the following free and clear of all encumbrances pursuant to 11 U.S.C. § 363(b) and (f) (collectively, the "**Patent Rights**"):

(a) the invention disclosures, provisional patent applications, patent applications and patents listed below (the "**Patents**");

(b) all provisional patent applications, patent applications, patents or other governmental grants or issuances (i) to which any of the Patents directly or indirectly claims priority and/or (ii) for which any of the Patents directly or indirectly forms a basis for priority;

(c) reissues, reexaminations, extensions, continuations, continuations in part, continuing prosecution applications, requests for continuing examinations, and divisions of any item in the foregoing categories (a) and (b);

(d) foreign patents, patent applications, and counterparts relating to any item in the foregoing categories (a) through (c), including, without limitation, certificates of invention, utility models, industrial design protection, design patent protection, and other governmental grants or issuances;

(e) items in any of the foregoing in categories (a) through (d), whether or not expressly listed as Patents below and whether or not claims in any of the foregoing have been rejected, withdrawn, cancelled, or the like;

(f) rights to all inventions, invention disclosures, and discoveries described in any item in the foregoing categories (a) through (e) and all other rights arising out of such inventions, invention disclosures, and discoveries;

(g) rights to apply in any or all countries of the world for patents, certificates of invention, utility models, industrial design protections, design patent protections, or other governmental grants or issuances of any type related to any item in the foregoing categories (a) through (f), including, without limitation, under the Paris Convention for the Protection of Industrial Property, the International Patent Cooperation Treaty, or any other convention, treaty, agreement, or understanding;

(h) causes of action (whether currently pending, filed, or otherwise) and other enforcement rights under, or on account of, any of the Patents and/or any item in any of the foregoing categories (a) through (g), including, without limitation, all causes of action and other enforcement rights for

- (i) damages,
- (ii) injunctive relief, and
- (iii) other remedies of any kind

for past, current, and future infringement; and

(i) all rights to collect royalties and other payments under or on account of any of the Patents and/or any item in the foregoing categories (b) through (h).

Patent or Application No.	Country	Filing Date	Title of Patent and First Named Inventor
US 6,764,683	US	December 13, 1999	Loop peptide and TGF-Alpha for stimulating stem cell proliferation and migration, Daniel Twardzik.
US 6,486,122	US	April 26, 2000	Methods of increasing body weight in a subject by administering TGF-Alpha Daniel Twardzik
US 6,677,307	US	May 1, 2002	TGF-Alpha polypeptides, functional fragments and methods of use therefore, Daniel Twardzik
US 6,815,418	US	August 17, 2001	TGF-Alpha polypeptides, functional fragments and methods of use therefor, Daniel Twardzik
10/893,172	US	July 16, 2004	Loop peptide and TGF-Alpha for stimulating stem cell proliferation and migration, Daniel Twardzik
09/492,935	US	January 27, 2000	
09/299,473	US	April 26, 1999	Method for stimulating hematopoiesis using TGF-Alpha, Daniel Twardzik
09/641,587	US	August 17, 2000	TGF-Alpha polypeptides, functional fragments and methods of use therefor, Daniel Twardzik
09/955,581	US	September 12, 2001	TGF-Alpha polypeptides, functional fragments and methods of use therefor, Daniel Twardzik
09/378,567	US	August 19, 1999	

Patent or Application No.	Country	Filing Date	Title of Patent and First Named Inventor
06/492,751	US	May 9, 1983	Biologically active polypeptides, George J. Todaro
06/598,136	US	April 12, 1984	Biologically active polypeptides, George J. Todaro
PCT/US02/26023	WO	August 16, 2002	TGF-Alpha [aka TGF- β G(A)] polypeptides, functional fragments and methods of use therefor, Daniel Twardzik
PCT/US00/11564	WO	April 26, 2000	TGF-Alpha polypeptides, functional fragments and methods of use therefor, Daniel Twardzik
PCT/US00/22882	WO	August 17, 2000	TGF-Alpha polypeptides, functional fragments and methods of use therefor, Daniel Twardzik
PCT/US03/13631	WO	April 30, 2003	TGF-Alpha polypeptides, functional fragments and methods of use therefor, Daniel Twardzik
CA 1,341,508	CA	April 26, 1984	Transforming growth factor peptides, George Joseph Todaro
CA 2,380,635	CA	August 17, 2000	TGF-Alpha, polypeptides, functional fragments and methods of use therefor, Daniel Twardzik
CA 2,371,241	CA	April 26, 2000	TGF-Alpha, polypeptides, functional fragments and methods of use therefor, Stefan L. Paskell
CA App 452,799	CA	April 26, 1984	Transforming growth factor peptides, George J. Todaro
CA App 518,293	CA	September 16, 1986	Transforming growth factor peptides, George J. Todaro
EP 00957614.1	EP	August 17, 2000	TGF-Alpha polypeptides, functional fragments and methods of use therefor, Daniel Twardzik

Patent or Application No.	Country	Filing Date	Title of Patent and First Named Inventor
EP 00928576.8	EP	April 26, 2000	TGF-Alpha polypeptides, functional fragments and methods of use therefor, Daniel Twardzik
JP 2000-614365	JP	April 26, 2000	TGF-Alpha polypeptides, functional fragments and methods of use therefor, Daniel Twardzik
JP 2001-516474	JP	August 17, 2000	TGF-Alpha polypeptides, functional fragments and methods of use therefor, Daniel Twardzik
AU 0069208	AU	August 17, 2000	TGF-Alpha polypeptides, functional fragments and methods of use therefor, Daniel Twardzik
AU 0046793	AU	April 26, 2000	TGF-Alpha polypeptides, functional fragments and methods of use therefor, Daniel Twardzik
AU 3228802	AU	April 30, 2003	TGF-Alpha polypeptides, functional fragments and methods of use therefor, Daniel Twardzik
10/050,190	US	January 15, 2002	TGF-Alpha polypeptides, functional fragments and methods of use therefor, Daniel Twardzik
10/039,119	US	January 4, 2002	TGF-Alpha polypeptides, functional fragments and methods of use therefor, Daniel Twardzik
09/961,227	US	September 20, 2001	Method of treatment of tumors using transforming growth factor-alpha, Alan Upshall
PCT/US01/29742	WO	September 20, 2001	Method of treatment of tumors using transforming growth factor-alpha, Alan Upshall
60/235,152	US	September 22, 2000	Method of treatment of tumors using transforming growth factor-alpha, Alan Upshall

Patent or Application No.	Country	Filing Date	Title of Patent and First Named Inventor
US 5240912	US	December 9, 1991	Transforming growth factor (TGF) peptides, George J. Todaro
US 4816561	US	September 17, 1985	Biologically active polypeptides, George J. Todaro
US 4863899	US	May 22, 1987	Biologically active polypeptides, George J. Todaro
06/598,136	US	April 12, 1984	Biologically active polypeptides, George J. Todaro
06/492,751	US	May 9, 1983	Biologically active polypeptides, George J. Todaro
07/053,240	US	May 22, 1987	Biologically active polypeptides, George J. Todaro
07/232,335	US	August 12, 1988	Biologically active polypeptides, George J. Todaro
07/346,846	US	May 2, 1989	Biologically active polypeptides, George J. Todaro
08/077,154	US	June 16, 1993	Biologically active polypeptides, George J. Todaro

Assignor makes this Assignment pursuant to the Court Order. As used herein, the "Court Order" means that certain Order Authorizing Employment and Payment of Auctioneer Pursuant to 11 U.S.C. §§ 327 and 328; 1) Approving Auction Listing Agreement and Bid Procedures, Including Minimum Bid Price, and 2) Authorizing Final Sale of Patent Portfolio Free and Clear of Interests Pursuant to 11 U.S.C. § 363(b) and (f) by Internet Auction, dated January 8, 2007, in the proceeding entitled *In re Kaleidos Pharma, Inc. EIN: 91-1719007*, United States Bankruptcy Court, Western District of Washington at Seattle, Case No. 05-26907-SJS.

Assignor hereby authorizes the respective patent office or governmental agency in each jurisdiction to issue any and all patents, certificates of invention, utility models or other governmental grants or issuances that may be granted upon any of the Patent Rights in the name of Assignee, as the assignee to the entire interest therein.

The terms and conditions of this Assignment of Patent Rights will inure to the benefit of Assignee, its successors, assigns, and other legal representatives as fully and entirely as the same would have been held by Assignor had this assignment not been made.

IN WITNESS WHEREOF this Assignment of Patent Rights is executed at Seattle, WA
on 4/3/07.

Edmund J. Wood; ("Assignor")

By: Edmund J. Wood

Name: _____

Title: _____

(Signature MUST be notarized)

STATE OF WA)
COUNTY OF King) ss.

On April 3, 07 before me, Tessa M. Oberlander Notary Public in
and for said State, personally appeared Edmund J. Wood, personally known to
me (or proved to me on the basis of satisfactory evidence) to be the person whose name is
subscribed to the within instrument and acknowledged to me that he/she executed the same in
his/her authorized capacity, and that by his/her signature on the instrument the person, or the
entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.

Signature Tessa M. Oberlander

